Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy

Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline

AstraZeneca invests additional $136 million to expand Qingdao inhalants facility

This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform

Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible

Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals

Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform

Eli Lilly to invest $1.2 billion in Puerto Rico to boost U.S. oral medicine production

FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency

Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.